Please login to the form below
BI
This page shows the latest BI news and features for those working in and with pharma, biotech and healthcare.
Gilead drug reduces HIV viral reservoir, says researcher
After starting ART, the patients also received bi-weekly doses of either vesatolimod or placebo as an add-on therapy, and then came off therapy while they were monitored for a
Latest news
-
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
Boehringer Ingelheim took a different tack with its Alzheimer’s candidate BI 409306, which targeted PDE9, but that drug also failed mid-stage testing and was unable to show any improvement
-
Boehringer bolsters NASH pipeline with Enleofen link-up
That has built on NASH-focused deals dating back several years including a 2015 alliance with Pharmaxis for AOC3 inhibitor BI 1467335 – now discontinued – and a $201m agreement with gene-silencing
-
Novartis picks up inclisiran after completion of MedCo acquisition
Repatha and Praluent are dosed more frequently – either monthly or bi-monthly.
-
Novartis acquires The Medicines Company for $9.7bn following takeover rumours
Repatha and Praluent are dosed more frequently – either monthly or bi-monthly.
-
GSK preps filings for BCMA-targeting multiple myeloma drug
idecabtagene vicleucel) slated for approval next year, and other drugs including a bi-specific antibody from Amgen called AMG 420.
Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout
Boehringer bolsters NASH pipeline with Enleofen link-up
Novartis picks up inclisiran after completion of MedCo acquisition
Novartis acquires The Medicines Company for $9.7bn following takeover rumours
GSK preps filings for BCMA-targeting multiple myeloma drug
More from news
Approximately 4 fully matching, plus 94 partially matching documents found.
Latest Intelligence
-
The ‘Million Hour Challenge’
Since the initiative launched, AstraZeneca has seen two consecutive increases in the bi-annual employee engagement survey, with 69% of AstraZeneca employees agreeing that ‘Together, we are making progress in our
-
Is it time we stopped talking about adherence?
attractive and valuable bi-product.
-
Deal Watch September 2016
Boehringer Ingelheim granted Amgen worldwide rights to BI 836909, a bispecific T cell engager designed to treat multiple myeloma. ... Under the agreement, Daiichi Sankyo will acquire a licence to Zymeworks' platforms to develop a bi-specific antibody
-
The human perspective
But you can deal with the other three factors. This is where Boehringer has a key strength because there is a very, very strong culture, which is built on our BI
-
Deal Watch April 2016
1, 200. ZymeWorks (US). GSK (UK). License and option. Preclinical bi-specific antibodies based on Azymetric platform for treatment of solid tumours.
The ‘Million Hour Challenge’
Is it time we stopped talking about adherence?
Deal Watch September 2016
The human perspective
More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.
Latest from PMHub
-
Origins Insights wins the “Best Patient-Centric Approach” award at the BHBIA BOBI Awards 2021
patient voice and the critical role of BI in ensuring this is heard.
-
Havas Lynx Group
AbbVie. ALK. Astellas. AstraZeneca. Bayer. Boehringer Ingelheim. BI. BMS. Celgene. Sanofi Genzyme.
-
CSL
CSL are a healthcare specialist business intelligence consultancy. We help companies utilise tools like Power BI &Tableau.
-
Visual Numbers Limited
visualising data to augment intelligence and reveal actionable insights using Tableau and Power BI.
-
New Leaf Technology Solutions Ltd
market in areas such as Incentive Compensation, KAM, Coaching, Collaboration platforms and BI sol.
Havas Lynx Group
More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital strategist
-
Competitive
-
Digital project manager
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
